BTC Health Limited Overview
| Field | Detail |
|---|---|
| Legal name | BTC Health Limited (styled "BTC health Limited" in some filings) |
| Former name | Biotech Capital Limited |
| ABN / ACN | ABN 45 091 979 172 / ACN 091 979 172 |
| Incorporated | 14 March 2000 (per TradingView company profile; consistent with ACN series) |
| Incorporation jurisdiction | Australia (public company limited by shares, domiciled in Australia — FY2026 Annual Report, Note 1) |
| Legal / tax status | Registered Pooled Development Fund under the Pooled Development Funds Act 1992 (Cth) |
| Accounting status | Investment entity under AASB 10; investees held at fair value through profit or loss (Level 3) |
| Headquarters / registered office | Level 1, 10 Oxley Road, Hawthorn VIC 3122, Australia |
| Previous office (data-provider records) | Suite 201, 697 Burke Road, Camberwell VIC 3124 |
| Exchange / ticker | Australian Securities Exchange, ASX: BTC (Yahoo/Reuters-style: BTC.AX) |
| ISIN | AU000000BTC7 |
| Other identifiers | FIGI BBG000C028N0; German WKN 552817 |
| CUSIP | Not applicable / not publicly disclosed (Australian security) |
| Fiscal year end | 30 June |
| Ordinary shares on issue | 357,454,456 (30 June 2026 and 14 August 2026) |
| Unlisted options | 21,000,000 |
| Shareholders | 981 holders (14 August 2026) |
| Auditor | RSM Australia Partners (Melbourne), lead partner A L Whittingham. Appointed at the 28 November 2025 AGM after a competitive tender, replacing Grant Thornton Audit Pty Ltd. |
| Share registry | Link Market Services Limited, Melbourne |
| Employees | Not publicly disclosed in the annual report. Third-party directory lists 11–50 employees across the group (annualreports.co.uk). |
| Market capitalisation | Approx. A$20–21 million. Based on a last observed share price of A$0.057–0.060 (InvestSMART, August 2026) × 357.45m shares. The live price as at 9 October 2026 should be verified. |
| Website | www.btchealth.com.au |
| Executive Chairman & Managing Director | Dr Richard Treagus |
| CFO & Company Secretary | Salesh Balak |
| Chief Operating Officer | Joshua Kahanovitz |
No change of listing or ticker has occurred.
| Metric | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
| Group employees (number) | — | — | — |
Not publicly disclosed. The annual report does not state a headcount. The KMP disclosure covers 5 individuals (3 directors, CFO and COO).
BTC Health is a micro-cap, Melbourne-based specialty medical-products distribution group wrapped inside a tax-advantaged Pooled Development Fund structure. Through three wholly owned investee companies — BTC Cardio, BTC Speciality Health and BTC Pharma — it in-licenses and distributes imported medical devices, consumables and specialty pharmaceuticals into Australian and New Zealand public and private hospitals. Its focus areas are cardiothoracic surgery, ECMO/critical care, post-operative pain, neuro-spinal procedures and respiratory medicine.
Group revenue was A$10.27m in FY2026 (unaudited). Since 2024 the business has pivoted decisively towards cardiac and critical care, anchored by the January 2025 takeover of Corcym's ANZ heart-valve business. Cardio now represents 57% of revenue. The group is near break-even at EBITDA level, debt-free, and dependent on exclusive supplier agreements and hospital procurement cycles.
Its investment case rests on four things: converting a large ECMO evaluation pipeline, rebuilding infusion-pump volumes, managing supply risk from a now-insolvent pharmaceutical manufacturer, and the PDF's tax-free capital-gains treatment for shareholders.
The company's own description
The FY2026 Annual Report and every recent ASX release use the same self-description. BTC Health describes itself as a Pooled Development Fund that actively invests in businesses which acquire, develop and distribute innovative medical products in Australia and New Zealand. It says it is building a group of high-growth businesses that together give access to some of the best specialised therapeutics and medical devices from around the world.
The FY2026 Directors' Report states its principal activity as follows: the company is a PDF registered under the PDF Act 1992 and invests in entities in the healthcare sector. It held direct interests in three investee companies at 30 June 2026 and continues to seek investment opportunities in healthcare.
The FY26 Investor Presentation adds the PDF rationale. PDFs exist to increase the supply of capital to SMEs. PDFs are taxed at 15% on income and gains from SME equity investments. Shareholders are exempt from tax on income and gains from holding and disposing of PDF shares.
Independent characterisation
Stripped of the PDF wrapper, BTC Health is an asset-light, exclusive-agency medical device and specialty pharmaceutical distributor for the ANZ market. Its key characteristics are:
-
No proprietary manufacturing and no meaningful R&D. Products are sourced from overseas or domestic manufacturers under exclusive or semi-exclusive distribution agreements. Examples include Corcym (Italy/UK), Eurosets (Italy), Exstent (UK), Micrel (Greece), IZI Medical (USA), Ilumark (Germany), Morpheus AG, Andocor NV (Belgium), SmartCanula LLC, Jafron Biomedical (China/HK) and Arna Pharma (Sydney).
-
Value-add is regulatory and commercial. BTC acts as Australian sponsor (TGA registration, ARTG listings and pharmacovigilance). It manages reimbursement — Prescribed List of Medical Devices for devices and the PBS for Bronchitol. It also handles hospital tendering, clinical evaluations, field clinical support, inventory holding and logistics.
-
The customer base is concentrated in hospitals. This means State public hospital systems (via purchase orders and tenders), private hospitals and specialist clinicians: cardiothoracic surgeons, perfusionists, intensivists, anaesthetists, interventional radiologists and respiratory physicians.
-
The model has three layers. The listed parent is a holding vehicle that funds working capital via interest-free loans (A$1.90m outstanding to BTC Cardio at 30 June 2026). The investees carry the operating P&L. Value is recognised at the parent through directors' DCF valuations.
Revenue model
| Revenue type | Share of group revenue | Comment |
|---|---|---|
| Product sales — implantable / single-use medical devices | Majority (Cardio 57% plus Neurospinal 13% in FY2026) | Heart valves, PEARS implants, cannulas, biopsy needles, markers, bone removal devices |
| Product sales — capital equipment | Included in Cardio (ECMO A$1.60m in FY2026) | Eurosets ECMO consoles and systems; lumpy, tender-driven |
| Product sales — consumables / disposables | Included in Infusion Pumps (19%) and Cardio | Elastomeric and electronic pump disposables, oxygenators, circuits |
| Specialty pharmaceuticals | 11% (FY2026) | Bronchitol (PBS-listed) and Aridol |
| Royalty income | Immaterial / not separately disclosed | Single-digit royalty from Arna Pharma on Singapore/Malaysia sales for 3 years from February 2025 (now at risk given Arna's administration) |
| Services, subscription, licensing-out | Nil disclosed | — |
| Statutory parent revenue | Interest income only: A$29,419 in FY2026 | Parent records no product revenue |
Value-chain position
BTC sits in the downstream commercialisation and distribution layer:
Manufacturer (offshore OEM) → [BTC: in-licensing, regulatory sponsorship, reimbursement listing, importation, warehousing, sales/clinical support] → Hospital procurement (State health purchasing bodies / private hospital groups) → Clinician / patient
Customer types and end-markets
| Customer type | End-market / clinical area | Investee |
|---|---|---|
| Public tertiary hospitals (cardiothoracic units, ICUs, paediatric hospitals) | Cardiac surgery, ECMO / extracorporeal life support, critical care, hemoperfusion | BTC Cardio |
| Private hospitals | Cardiac surgery (valves, PEARS), post-operative pain | BTC Cardio, BTC Speciality Health |
| Surgical / anaesthesia departments | Post-operative pain management (elastomeric and electronic ambulatory infusion pumps) | BTC Speciality Health |
| Interventional radiology / spine | Tissue biopsy, image-guided surgery markers, bone removal | BTC Speciality Health |
| Respiratory physicians, cystic fibrosis clinics, lung function labs; community and hospital pharmacy | Cystic fibrosis therapy (Bronchitol); bronchial challenge testing (Aridol) | BTC Pharma |
Geography: Australia and New Zealand only (FY2026 Annual Report, Note 3 — single segment, single geography: Australia).
Strategy
Stated strategy — recurring themes
The themes below are drawn from the FY2026 AR, the FY26 Investor Presentation and the November 2025 AGM address.
-
Mission statement: "Improving patients' lives through global medical innovation" (presentation tagline).
-
Build a diversified specialty medical products group. The AGM 2025 address describes reshaping the business into a more diversified medical products company that is less dependent on a single product line.
-
Strengthen the core business (FY26 Strategy slide):
-
reset the cost base
-
improve margins in core businesses
-
prioritise cash flow and balance-sheet strength
-
diversified growth
-
-
Diversification as resilience. The FY26 presentation states that no single product line represents more than a quarter of group revenue. This claim is consistent at product-line level; Corcym valves at A$2.34m are about 23%.
-
Ongoing strategic review of investments to ensure they generate sustainable cash flows and profitability (FY2026 Directors' Report).
-
Continued search for new healthcare investments in technologies and companies that would benefit from management expertise and development capital.
FY2027 priorities (FY2026 AR and FY26 Update)
| # | Priority | Measurable indicator to watch |
|---|---|---|
| 1 | Convert the advanced ECMO evaluation pipeline into State public hospital contracts | ECMO revenue (FY2026 A$1.60m vs FY2025 A$2.29m); new contract announcements |
| 2 | Increase Perceval Plus heart-valve utilisation in established centres | Corcym revenue growth on A$2.34m base |
| 3 | Complete conversion of infusion pump users to Micrel and Elasto-Q | Pump revenue stabilising above A$1.92m |
| 4 | Expand the neurospinal customer base and add new pharmaceutical products to BTC Pharma | Neurospinal revenue (A$1.39m); new pharma in-licensing, now urgent given Arna |
| 5 | Hold the reset cost base (about A$4.2m) while revenue scales | Opex / sales below 41% |
Board objective: Build on FY2026's positive EBITDA toward sustainable profitability.
Initiatives announced in the last 24 months (Oct 2024 – Oct 2026)
| Date | Initiative | Type | Status |
|---|---|---|---|
| 1 Nov 2024 | Micrel and Elasto-Q listed on the Prescribed List | Reimbursement / product transition | Done; conversion ongoing |
| Dec 2024 | Corcym ANZ heart-valve business assumed (effective 1 Jan 2025) | Business acquisition / partnership | Integrated |
| H1 FY2025 | RCH Melbourne 5-year A$5m ECMO contract | Contract | Executing |
| Feb 2025 | Arna Pharma licence made indefinite; ROFR on Arna pipeline; SG/MY rights monetised via royalty | Partnership | Impaired by Arna administration (Sep 2026) |
| Mar 2025 | New CFO / Company Secretary and COO appointments | Leadership | Done |
| Jul 2025 | Adelaide WCH ECMO order (A$0.5m) | Contract | Installed Jul 2025 |
| FY2026 | Andocor CPB cannulas launched | New product line | A$0.73m first-year revenue |
| FY2026 | SmartCanula exclusive ANZ agreement | Partnership | Ramping in FY2027 |
| Nov–Dec 2025 | A$1.96m placement to professional and sophisticated investors | Capital | Completed 2 Dec 2025 |
| FY2026 | In-sourcing of company secretarial and tax work | Cost programme | Accounting/secretarial costs fell from A$88k to A$3k |
| 13 Feb 2026 | Jafron Biomedical hemoperfusion exclusive ANZ distribution | Partnership | Ramping in FY2027 |
| Nov 2025 | Auditor change to RSM after tender | Governance | Done |
| Sep 2026 | Engagement with Arna administrators, TGA and Department of Health on continuity of supply | Crisis management | Ongoing |
ESG and sustainability commitments
No quantified ESG commitments are disclosed. Climate risk is acknowledged qualitatively in the risk section.
Medium-term targets and guidance
| Target | Source | Outcome |
|---|---|---|
| FY2025: positive EBITDA and clear pathway to sustainable profit | HY25 Update | Group EBITDA A$3k (technically positive); adjusted A$0.18m |
| FY2026: double-digit revenue growth | AGM 2025, HY26 presentation | Missed (+0.4%) |
| FY2027: no numeric guidance; qualitative objective to build on positive EBITDA toward sustainable profitability | FY2026 AR | — |
| FY2027 Pharma: Bronchitol/Aridol sales up to A$0.5m without further supply (vs A$1.1m in FY2026) | ASX 8 Sep 2026 | Negative guidance revision |
Products & Services
Pricing is not publicly disclosed for any product. Reimbursement status is noted where disclosed.
BTC Cardio — Cardiothoracic & Critical Care (57% of FY2026 revenue)
| Product / brand | Supplier (country) | Description and capabilities | Target customer | Year / status | Commercial notes |
|---|---|---|---|---|---|
| Corcym heart valves, incl. Perceval Plus | Corcym Srl (Italy/UK; formerly LivaNova's heart-valve business) | Surgical aortic heart valve portfolio. Perceval Plus is a sutureless, self-anchoring bioprosthetic aortic valve that reduces cross-clamp time. The full ANZ valve range distributed is not itemised in filings. | Cardiothoracic surgeons; public and private cardiac centres | BTC responsibility from 1 Jan 2025 | FY2026 revenue A$2.34m (+91%). FY27 priority is higher Perceval Plus utilisation in established centres. |
| Eurosets ECMO / ECLS systems (ECMOLIFE, COLIBRI, Landing Advance, ECLS heater-coolers, oxygenators incl. NEOLA) | Eurosets Srl (Italy) | Extracorporeal membrane oxygenation consoles, circuits and oxygenators for adult, paediatric and neonatal life support; heater-cooler units. Landing Advance received TGA approval on 1 May 2024. | ICUs, paediatric hospitals, perfusion departments | Exclusive ANZ since Dec 2023 | FY2026 revenue A$1.60m (FY2025 A$2.29m). RCH Melbourne A$5m / 5-year contract; Adelaide WCH A$0.5m order (Jul 2025). Evaluations "well advanced across most major public hospitals". |
| PEARS (Personalised External Aortic Root Support, "ExoVasc") | Exstent Ltd (UK) | Custom-made mesh sleeve manufactured from patient CT imaging to support a dilated aortic root (e.g. Marfan syndrome) without replacing it | Cardiothoracic surgeons | Exclusive ANZ since Apr 2024 | FY2026 revenue A$1.10m (+20%) |
| Cardiopulmonary bypass (CPB) cannulas | Andocor NV (Belgium) | Arterial and venous cannulas for connecting patients to the heart-lung machine | Perfusionists, cardiac surgeons | Introduced FY2026 | First-year revenue A$0.73m |
| SmartCanula venous cannulas | SmartCanula LLC | Self-expanding venous drainage cannulas for CPB and ECMO | Perfusion, cardiac surgery, ECMO teams | Exclusive ANZ, signed FY2026 | Not material to FY2026 revenue; expected to build through FY27 |
| Jafron hemoperfusion cartridges (HA-series and related) | Jafron Biomedical (HK) Co Ltd (China) | Sorbent hemoperfusion cartridges for blood purification in sepsis, cytokine storm, liver failure and critical care, used with CRRT/ECMO circuits | ICUs, nephrology / critical care | Exclusive ANZ, announced 13 Feb 2026 | Not material to FY2026 revenue; requires market development |
| LPS Adsorber (endotoxin adsorber) | Not confirmed in filings (listed in Morningstar product description) | Extracorporeal endotoxin removal | ICU | — | — |
| Cardiothoracic surgical instruments | Wexler (exclusive agreement 15 May 2024) — product scope inferred | Surgical instruments for cardiothoracic procedures (FY2026 AR lists "cardiothoracic surgical instruments" in BTC Cardio portfolio) | Cardiothoracic theatres | Since 2024 | Revenue not separately disclosed |
BTC Speciality Health — Post-Operative Pain (19% of FY2026 revenue)
| Product / brand | Supplier | Description | Target customer | Year / status | Commercial notes |
|---|---|---|---|---|---|
| ambIT electronic ambulatory infusion pumps | Formerly via Admedus Infusion heritage | Programmable ambulatory pumps for post-operative regional anaesthesia / pain | Anaesthetists, surgical wards | Discontinued | Previously dominated group revenue; user base being converted. Its exit is the main reason for the FY2023 write-down and FY2025–26 pump revenue decline. |
| Micrel ("Rythmic" / Rhythm Evolution) electronic infusion pumps | Micrel Medical Devices (Greece) | Ambulatory electronic infusion pumps for pain management and other therapies | Anaesthetists, acute pain services | On Prescribed List since 1 Nov 2024 | Conversion of ambIT users ongoing |
| Elasto-Q elastomeric pumps | Not named in filings | Disposable, non-electronic elastomeric infusion pumps for continuous local anaesthetic delivery | Surgeons, anaesthetists | On Prescribed List since 1 Nov 2024 | Conversion ongoing |
| Infusion and nerve catheter kits; TIVA products | Various | Consumable kits for regional nerve blocks; total intravenous anaesthesia accessories | Anaesthesia departments | Ongoing | Revenue not separately disclosed |
Total infusion pump revenue was A$1.92m in FY2026, down 35% from about A$2.95m.
BTC Speciality Health — Neuro-Spinal / Interventional (13% of FY2026 revenue)
| Product / brand | Supplier | Description | Target customer | Year / status | Commercial notes |
|---|---|---|---|---|---|
| IZI Medical biopsy needles, incl. Bonopty coaxial bone biopsy system | IZI Medical Products (USA) | Single-use tissue and bone biopsy, interventional radiology products | Interventional radiologists, spine surgeons | Exclusive ANZ (announcement drove a 27% share-price jump) | Part of A$1.39m neurospinal revenue |
| Ilumark radiological / navigation markers | Ilumark GmbH (Germany; wholly owned by IZI) | Single-use reflective markers for image-guided surgical navigation | Neurosurgery, orthopaedic and spine theatres | Exclusive ANZ | Part of A$1.39m |
| Rebellion bone removal system | Morpheus AG | Bone cutting / removal device for spine and cranial surgery | Spine and neurosurgeons | Exclusive ANZ since Dec 2023 | Part of A$1.39m |
| TeDan products | TeDan Surgical Innovations (agreement 5 Jun 2024) | Scope not detailed in sources reviewed (TeDan is a surgical retractor specialist; mapping to neuro-spinal is inferred) | Surgeons | Since 2024 | — |
Neurospinal revenue was A$1.39m in FY2026 (down 9%). The FY27 priority is expanding the customer base.
BTC Pharma — Specialty Pharmaceuticals (11% of FY2026 revenue)
| Product | Manufacturer / licensor | Description | Target customer | Regulatory / reimbursement | Commercial notes |
|---|---|---|---|---|---|
| Bronchitol (mannitol 40mg inhalation powder, hard capsule; AUST R 168002) | Arna Pharma Pty Ltd (Sydney; ex-Pharmaxis) | Inhaled osmotic agent that improves mucus clearance in cystic fibrosis | CF clinics, respiratory physicians, pharmacies | TGA-registered; PBS-listed; BTC Pharma is sponsor | FY2026 revenue declined on competitive pressure. TGA anticipated shortage from 1 Apr 2027. About 8 months of stock held at 8 Sep 2026. |
| Aridol (mannitol bronchial challenge test, composite pack; AUST R 116832) | Arna Pharma | Inhaled diagnostic test for bronchial hyper-responsiveness (asthma diagnosis) | Lung function laboratories, respiratory physicians | TGA-registered; BTC Pharma is sponsor | Less than 1 month of stock at 8 Sep 2026. TGA anticipated shortage from 1 Oct 2026. |
Combined Bronchitol + Aridol revenue was A$1.10m in FY2026 (FY2025 A$1.26m). BTC Pharma was the most profitable investee, with EBITDA of A$0.36m. After the Arna administration, the company guides to FY2027 sales of up to A$0.5m if supply does not resume.
Financial Narrative
Because of the investment-entity structure, this section presents two parallel financial sets:
6A — Group (unaudited, look-through operating business): Source: FY26 Investor Presentation, slide 9, and FY26 / HY26 Updates.
6B — Statutory parent (audited): Source: FY2026 Annual Report, including its 5-year remuneration-report table, and prior filings.
6A. Group operating performance (unaudited, consolidated non-statutory)
Table 6A.1 — Income statement metrics: notes and sources
Notes: FY2025 and FY2026 are exact disclosed figures (FY2025: revenue A$10,232,894, EBITDA A$2,770; FY2026: revenue A$10,271,312, EBITDA A$137,721). FY2022–FY2024 are read from presentation charts, which are rounded. Group operating income (EBIT), pre-tax income and net income on a consolidated basis are not publicly disclosed.
Table 6A.3 — Half-yearly progression
Notes: H2 figures are derived as full year less H1. H2 FY2026 revenue of A$5.29m is confirmed in the FY26 Investor Presentation. H2 FY2025 is fully derived.
Group revenue CAGR FY2022–FY2026: about 7.5% per year (A$7.7m to A$10.27m over 4 years). The FY2022–FY2024 CAGR was about 3.2%. The FY2024–FY2026 CAGR was about 11.9%, driven almost entirely by the Corcym acquisition.
Commentary — Group P&L
Revenue. Three distinct phases are visible:
-
FY2022–FY2024 stagnation (A$7.7m to A$8.2m). The ambIT pump business was mature and then discontinued.
-
FY2025 step-up (+25% to A$10.23m). This came from a half-year of Corcym heart valves, ECMO capital sales (A$2.29m) and PEARS.
-
FY2026 plateau (A$10.27m, +0.4%). A full year of Corcym (+91%) and new cannulas (A$0.73m) were almost exactly offset by declines in pumps (−35%), ECMO (−30%), pharma (−13%) and neurospinal (−9%).
Management explicitly missed its double-digit revenue growth target. It attributed the miss to State public hospital purchase-order timing on ECMO.
Gross margin. Margin has been range-bound at 40–45%. The FY2024 peak of 45% likely reflects ambIT inventory sell-through at full margin (the FY2023 4E flagged remaining ambIT stock to be sold). FY2025–26 at about 42% reflects a mix shift to heart valves and capital equipment, where distribution margins are typically thinner than on proprietary-like consumables. This is an analyst inference; product-level margins are not disclosed.
Operating expenses. Opex rose from A$3.9m to A$4.3m in FY2025 with Corcym integration and the cardio sales force, then fell 2% to A$4.23m in FY2026. The decline came from bringing company secretarial and tax work in-house and from other cost actions. Operating leverage is now the central thesis: opex is about 41% of sales against a gross margin of about 42.5%, so each incremental A$1m of revenue at constant margin would add roughly A$0.4m of EBITDA if the cost base is held.
EBITDA. Group EBITDA improved from −A$0.7m (FY2023) to +A$0.14m (FY2026). It remains thin (1.3% margin) and highly sensitive to ECMO order timing. H2 FY2026 EBITDA of A$0.24m is the best half in the five-year series.
6B. Statutory parent financials (audited)
Table 6B.4 — Statutory balance sheet (AUD)
Notes: - FY2022 and FY2023 cash are derived from FY2024 closing cash (A$2,022,155) and change-in-cash data from aggregators (FY2024 +A$0.29m, FY2023 −A$0.43m). They are approximate.
-
FY2024 investments are the FY2025 opening balance.
-
Goodwill and intangibles at investee level are not disclosed. Licence values are embedded in the fair value of investments, e.g. BTC Pharma's value reflects the Arna licence.
-
The A$141,348 insurance premium funding facility drawn in August 2025 was fully repaid within FY2026.
Table 6B.5 — Group cash (look-through, unaudited)
FY2024 group cash is not disclosed in the documents reviewed.
Table 6B.6 — Statutory cash flow (AUD)
Notes: FY2022–FY2024 OCF are from stoxray/InvestSMART aggregators and are consistent with InvestSMART's −A$0.4m to −A$0.43m. FY2025–FY2026 are audited. Group-level (consolidated) OCF, capex and FCF are not publicly disclosed.
Table 6B.7 — Ratios
Notes: ROIC, interest coverage, asset turnover and cash conversion cycle are not meaningful or not disclosed. The group carries no debt (interest expense was only A$4,993 on a premium funding facility in FY2026). Consolidated balance sheets, inventory, receivables and payables of investees are not published. Net debt / EBITDA is not meaningful because the company has net cash.
Commentary — Statutory accounts
Earnings quality. Statutory earnings are almost entirely a function of directors' Level 3 DCF valuations:
-
FY2023's A$9.62m write-down produced a A$10.17m loss.
-
FY2025's A$4.65m uplift (post-Corcym) produced a A$3.98m profit.
-
FY2026's A$0.43m net gain produced a A$34,728 profit.
These movements are non-cash. The parent's underlying cash burn is a steady A$0.35–0.50m per year, partly offset by interest income. Investors should anchor on group EBITDA and cash, not statutory EPS.
FY2026 valuation dynamics. Total investment value rose 5.7% to A$7.99m, but the mix shifted sharply:
The discount rates used were 20.0–21.33% pre-tax and 15–16% post-tax, applying a 5% growth rate on licensed products only, with pipeline products excluded.
Balance sheet. The balance sheet is clean: no debt, A$1.47m parent cash and A$11.2m net assets (3.14c NTA per share). However:
-
About 70% of total assets are Level 3 unlisted valuations and 17% are interest-free, on-demand loans to BTC Cardio.
-
RSM flagged both investment valuation and going concern as Key Audit Matters for FY2026. Going concern was supported by cash-flow forecasts to August 2027.
-
There are A$30.1m of unrecognised carried-forward tax losses (A$29.2m revenue, A$0.9m capital). These do not expire, but their utility is limited by PDF tax rules and profit generation.
Equity history. Issued capital is A$58.56m against accumulated losses of A$48.10m. Over its life, the company has consumed most of the capital raised.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Group Entities
| Entity | Ownership | Incorporation | Role |
|---|---|---|---|
BTC Health Limited | Listed parent (PDF) | Australia | Holding company, capital allocator, funds investee working capital |
BTC Cardio Pty Ltd | 100% | Australia | Cardiology, cardiothoracic and critical care products (Corcym, Eurosets, PEARS, cannulas, SmartCanula, Jafron) |
BTC Speciality Health Pty Ltd | 100% | Australia | Distributor of medical devices, consumables and specialty pharmaceuticals to ANZ hospitals. Two product lines: post-operative pain (infusion pumps) and neuro-spinal. |
BTC Pharma Pty Ltd (formerly BioImpact) | 100% | Australia | Licenses specialty pharmaceuticals (Bronchitol, Aridol). Can sublicense to BTC Speciality Health. TGA sponsor. |
Revenue by Segment
| Segment (AUD Mn) | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Cardio revenue | — | 4.48 | 5.86 |
Infusion Pumps revenue | — | 2.95 | 1.92 |
Neurospinal revenue | — | 1.53 | 1.39 |
Pharma revenue | — | 1.26 | 1.10 |
Group total revenue | 8.2 | 10.23 | 10.27 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansSegment share (%)
| Segment share (%) | FY2025 | FY2026 |
|---|---|---|
Cardio | 44 | 57 |
Infusion Pumps | 29 | 19 |
Neurospinal | 15 | 13 |
Pharma | 12 | 11 |
Segment Overview
| Segment | YoY growth (%) |
|---|---|
Cardio | 31 |
Infusion Pumps | -35 |
Neurospinal | -9 |
Pharma | -13 |
Group | 0.4 |
Investee revenue (AUD Mn)
| Investee revenue (AUD Mn) | FY2025 | FY2026 |
|---|---|---|
BTC Cardio revenue | 4.48 | 5.86 |
BTC Speciality Health revenue | 4.49 | 3.31 |
BTC Pharma revenue | 1.26 | 1.10 |
Segment EBITDA (AUD Mn)
| Segment EBITDA (AUD Mn) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
BTC Cardio EBITDA | — | — | — | -0.07 | 0.17 |
BTC Pharma EBITDA | — | — | — | — | 0.36 |
Total investee companies EBITDA | 0.2 | -0.1 | 0.5 | 0.5 | 0.5 |
Group EBITDA (after parent costs) | -0.5 | -0.7 | -0.2 | 0.0 | 0.14 |
Revenue by Segment (FY2025–FY2026)
| Cardio sub-line (AUD Mn) | FY2025 | FY2026 |
|---|---|---|
Corcym heart valves | 1.23 | 2.34 |
Eurosets ECMO | 2.29 | 1.60 |
PEARS aortic root support | 0.92 | 1.10 |
CPB cannulas (Andocor) | 0 | 0.73 |
Income Statement
| Metric (AUD Mn) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Group revenue | 7.7 | 7.8 | 8.2 | 10.23 | 10.27 |
Cost of sales | — | — | — | 5.91 | 5.91 |
Gross profit | 3.3 | 3.1 | 3.6 | 4.32 | 4.36 |
Operating expenses | 3.8 | 3.8 | 3.9 | 4.32 | 4.23 |
Group EBITDA | -0.5 | -0.7 | -0.2 | 0.003 | 0.14 |
Adjusted EBITDA (ex non-recurring) | — | — | — | 0.18 | 0.27 |
Non-recurring items | — | — | — | 0.18 | 0.13 |
Investee companies EBITDA | 0.2 | -0.1 | 0.5 | 0.5 | 0.5 |
Margin (%)
| Margin (%) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Gross margin | 43 | 40 | 45 | 42.2 | 42.5 |
Operating cost ratio (opex / revenue) | 49.4 | 48.7 | 47.6 | 42.2 | 41.1 |
EBITDA margin | -6.5 | -9.0 | -2.4 | 0.03 | 1.3 |
Adjusted EBITDA margin | — | — | — | 1.8 | 2.6 |
Income Statement (Half-Yearly)
| Metric (AUD Mn) | H1 FY2025 | H2 FY2025 | H1 FY2026 | H2 FY2026 |
|---|---|---|---|---|
Group revenue | 5.34 | 4.89 | 4.98 | 5.29 |
Group EBITDA | 0.26 | -0.26 | -0.10 | 0.24 |
Adjusted EBITDA | 0.33 | -0.15 | -0.01 | 0.27 |
Income Statement (AUD)
| Metric (AUD) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Revenue and other income (interest) | 95,004 | 13,260 | 16,360 | 9,960 | 29,419 |
Investment fair value adjustment | 0 | -9,619,890 | 1,714,809 | 4,646,820 | 433,135 |
Total expenses (ex FV) | — | — | — | 675,482 | 427,826 |
Net profit / (loss) after tax | -576,076 | -10,167,862 | 1,055,287 | 3,981,298 | 34,728 |
Income tax expense | 0 | 0 | 0 | 0 | 0 |
Per share
| Per share | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Basic EPS (cents) | -0.20 | -3.61 | 0.33 | 1.23 | 0.01 |
Diluted EPS (cents) | — | — | — | 1.18 | 0.01 |
Dividends per share (cents) | 0 | 0 | 0 | 0 | 0 |
NTA per share (cents) | — | — | — | 2.81 | 3.14 |
Share price at year end (AUD) | 0.040 | 0.026 | 0.038 | 0.060 | 0.055 |
Expense line (AUD)
| Expense line (AUD) | FY2025 | FY2026 |
|---|---|---|
Executive director fees | 40,000 | 40,000 |
Non-executive director fees | 80,000 | 80,000 |
Accounting and company secretarial | 88,369 | 2,625 |
Legal fees | 2,199 | 0 |
Share-based payments | 171,508 | 66,092 |
Audit fees | 121,800 | 102,250 |
Insurance | 82,546 | 62,001 |
Interest expense | 0 | 4,993 |
Other expenses | 89,060 | 69,865 |
Balance Sheet (AUD)
| Metric (AUD) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Cash and cash equivalents | 2,160,000 | 1,730,000 | 2,022,155 | 620,109 | 1,474,885 |
Investments at fair value (Level 3) | — | — | 2,914,809 | 7,561,629 | 7,994,764 |
Loans to investee companies | — | — | — | 1,158,668 | 1,900,000 |
Total assets | — | — | — | 9,358,415 | 11,385,074 |
Total liabilities | — | — | — | 201,950 | 177,801 |
Total debt | 0 | 0 | 0 | 0 | 0 |
Net debt (negative = net cash) | -2,160,000 | -1,730,000 | -2,022,155 | -620,109 | -1,474,885 |
Net assets / equity | 12,861,964 | 2,779,930 | 4,944,859 | 9,156,465 | 11,207,273 |
Goodwill and intangibles | 0 | 0 | 0 | 0 | 0 |
Working capital (current assets less current liabilities) | — | — | — | 436,168 | 1,312,509 |
Key Financials
| Metric (AUD Mn) | FY2022 | FY2023 | FY2025 | FY2026 |
|---|---|---|---|---|
Group cash (BTC plus investees) | 2.4 | 2.1 | 1.29 | 2.08 |
Cash Flow (AUD)
| Metric (AUD) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Operating cash flow | -392,911 | -433,608 | -404,757 | -499,981 | -353,880 |
Capex | 0 | 0 | 0 | 0 | 0 |
Free cash flow (OCF less capex) | -392,911 | -433,608 | -404,757 | -499,981 | -353,880 |
Loans advanced to investees | — | — | — | -960,865 | -741,332 |
Net proceeds from share issues / option exercises | — | — | — | 58,800 | 1,949,988 |
Dividends paid | 0 | 0 | 0 | 0 | 0 |
Share buybacks | 0 | 0 | 0 | 0 | 0 |
Net change in cash | -198,480 | -433,590 | 290,000 | -1,402,046 | 854,776 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Ratio | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Statutory ROE on closing equity (%) | -4.5 | -365.8 | 21.3 | 43.5 | 0.3 |
Statutory ROE on average equity (%) | — | -130.0 | 27.3 | 56.5 | 0.3 |
Statutory ROA on closing assets (%) | — | — | — | 42.5 | 0.3 |
Current ratio (x) | — | — | — | 3.16 | 8.38 |
Debt / equity (x) | 0 | 0 | 0 | 0 | 0 |
Financial Analysis
| Investee | FY2025 value (AUD) | FY2026 value (AUD) | Change (AUD) | Driver |
|---|---|---|---|---|
BTC Cardio | 1,165,431 | 3,458,246 | +2.29m | Full year of Corcym, PEARS and cannula growth |
BTC Speciality Health | 4,277,281 | 3,001,810 | −1.28m | Weaker Elasto-Q/Micrel uptake replacing ambIT |
BTC Pharma | 2,118,917 | 1,534,708 | −0.58m | Bronchitol competitive pressure |
Region revenue (AUD Mn)
| Region revenue (AUD Mn) | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Australia and New Zealand (group, unaudited) | 8.2 | 10.23 | 10.27 |
Rest of world | 0 | 0 | 0 |
Operating Areas
| Area | Direction | Reason |
|---|---|---|
Cardiac surgery (valves, PEARS, cannulas) | Fastest growing (+31% Cardio) | Corcym full year; new Andocor cannulas; PEARS adoption |
ECMO capital equipment | Declining in FY2026 (−30%) | State public hospital purchase-order timing; evaluations completed but not converted |
Post-operative pain (pumps) | Declining (−35%) | Planned exit of ambIT; slower-than-hoped conversion to Micrel/Elasto-Q |
Respiratory pharma | Declining (−13%), with acute FY2027 risk | Competitive pressure on Bronchitol; manufacturer insolvency |
Neuro-spinal | Declining (−9%) | Mature, established products; customer base not expanding |
Valuation Snapshot
| Metric | Value | Source / note |
|---|---|---|
Latest observed share price | A$0.057–0.060 | InvestSMART after the 20 Aug 2026 release. |
Shares on issue | 357,454,456 | FY2026 AR |
Market capitalisation | About A$20.4m at A$0.057; about A$21.4m at A$0.060 | Calculated |
52-week range (to Feb 2026) | A$0.051 – A$0.070 | StockLight |
Average daily volume | About 175,000 shares (historical) | InvestSMART / MarketIndex |
Analyst coverage | None. No major broker covers BTC. | MarketIndex |
Share price (AUD)
| Share price (AUD) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Year-end share price | 0.040 | 0.026 | 0.038 | 0.060 | 0.055 |
Share Price History
| Period | Start price (approx., AUD) | End price (approx., AUD) | Change (approx.) |
|---|---|---|---|
1-year (Oct 2025 – Oct 2026) | 0.061 | 0.057 | −7% |
3-year (Oct 2023 – Oct 2026) | about 0.06 (52-week high of 0.07 on 13 Nov 2023) | 0.057 | about −5% |
5-year (Oct 2021 – Oct 2026) | about 0.085 (Nov 2021 NTA-release prices) | 0.057 | about −33% |
Fiscal-year basis (30 Jun 2023 – 30 Jun 2026) | 0.026 | 0.055 | +112% |
Valuation Multiples
| Multiple | BTC Health | Basis |
|---|---|---|
Price / earnings (statutory) | About 590x | Not meaningful; FY2026 EPS 0.01c |
Price / book (statutory NAV) | 1.82x | A$20.4m / A$11.21m |
Price / NTA | 1.82x | 5.7c / 3.14c |
EV / Sales (group; EV = market cap less group cash of A$2.08m) | 1.8x | A$18.3m / A$10.27m |
EV / EBITDA (group adjusted) | About 68x | A$18.3m / A$0.27m |
EV / EBITDA (group reported) | About 131x | A$18.3m / A$0.14m |
Capital Markets
| Item | Status |
|---|---|
Dividend history | Last dividends paid in May 2011, Jul 2011 and Nov 2012. No dividends paid, recommended or declared in FY2025 or FY2026. No DRP. |
Dividend policy | None stated. Accumulated losses of A$48.1m. |
Credit ratings (Moody's / S&P / Fitch) | Not rated |
Debt maturity profile | No debt. A A$141,348 premium funding facility (Aug 2025) was fully repaid. |
DPS (AUD cents)
| DPS (AUD cents) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Dividends per share | 0 | 0 | 0 | 0 | 0 |
Share Price & Returns
| Date | Action | Shares | Price (AUD) | Proceeds |
|---|---|---|---|---|
FY2025 | Option exercises | 1,200,000 | 0.049 | A$58,800 |
2 Dec 2025 | Placement | 32,131,148 | 0.061 | A$1.96m gross; A$1.95m net |
Pending | Possible royalty-share issues to GLK / Kingfisher / Tau (related parties) | Determined at 30-day VWAP less 10% | — | A$187,549 royalties accrued; election deferred to 30 Jun 2027 |
Analyst Conclusions
Management guidance
There is no quantitative revenue or EBITDA guidance for FY2027. Management's qualitative objective is to build on positive EBITDA toward sustainable profitability, through five priorities:
-
ECMO conversion
-
Perceval Plus utilisation
-
Pump conversion
-
Neurospinal expansion and new pharma products
-
Holding the cost base
Explicit negative guidance (8 September 2026): Bronchitol/Aridol sales of up to A$0.5m in FY2027 without further supply, versus A$1.1m in FY2026.
Consensus
None. There is no sell-side coverage, so no consensus growth expectations exist.
Illustrative FY2027 bridge (analyst framework, not a forecast)
| Driver | Indicative revenue impact vs FY2026 (AUD Mn) |
|---|---|
| Pharma (Arna supply interruption) | Down by up to 0.6 |
| ECMO recovery to FY2025 level | Up by up to 0.7 |
| Corcym utilisation growth | Positive, unquantified |
| New agencies (SmartCanula, Andocor full year, Jafron) | Positive, unquantified |
| Pump conversion | Stabilisation to modest recovery |
Net effect: On this framework, holding FY2026 group revenue of about A$10.3m depends on cardio execution offsetting the pharma loss. EBITDA is at risk because the lost revenue is BTC Pharma's, the group's highest-margin and most profitable investee.
Bull case
-
Operating leverage on a reset cost base. Opex is A$4.23m (41.1% of sales) and gross margin 42.5%. H2 FY2026 already delivered A$0.24m EBITDA on A$5.29m revenue. Annualising the H2 run-rate plus ECMO recovery and new agencies could plausibly lift group EBITDA towards A$0.5–1.0m. On that basis, an EV of about A$18m would look inexpensive for a debt-free, tax-advantaged vehicle.
-
Cardio is a credible growth franchise. Revenue rose from A$4.48m to A$5.86m (+31%), and BTC Cardio swung from −A$0.07m to +A$0.17m EBITDA. Three new agencies sell into the same customers, and the RCH contract provides a multi-year base.
-
Asset backing plus tax shelter. NTA is 3.14c per share, there is no debt and there are A$30.1m of tax losses. Shareholder-level PDF tax exemption on gains provides downside support and appeal to concentrated, patient holders (NAOS 23.8%; insiders about 21%).
Bear case
-
The most profitable unit is impaired. BTC Pharma contributed A$0.36m EBITDA — more than the whole group's A$0.14m reported EBITDA. Its sole manufacturer is in administration, and TGA shortages are anticipated from October 2026 (Aridol) and April 2027 (Bronchitol). Absent a supply solution, FY2027 group EBITDA could fall back to a loss, and the Pharma carrying value (A$1.53m) faces write-down.
-
Growth has repeatedly disappointed. The FY2026 double-digit target was missed. ECMO conversion has slipped for at least two halves. Pumps fell 35%. The FY2022–FY2024 revenue CAGR was only about 3%. Statutory profits have depended on directors' Level 3 valuations, and the auditor flagged both valuation and going concern as Key Audit Matters.
-
Structural fragility and governance. The group is sub-scale (A$10m revenue) and reliant on terminable agencies. Parent cash burn is about A$0.35–0.5m per year, plus investee funding needs (A$1.9m loaned to Cardio), which points to likely further dilution. Governance is concentrated: combined Chair/MD, a three-person board, and related-party share-settled royalty arrangements. There is no analyst coverage and liquidity is thin.
Key catalysts and monitorables (next 12 months)
| Timing | Catalyst / monitorable |
|---|---|
| Ongoing (Oct 2026 →) | Outcome of the Arna Pharma administration: recapitalisation, sale, or liquidation; any alternative manufacturing or supply arrangement; TGA shortage status updates |
| Monthly | NTA statements, especially any BTC Pharma valuation change post-Arna |
| Nov 2026 (expected) | AGM and Chairman's address. Expiry of 6m A$0.12 options (23 Nov 2026). Board composition and auditor matters. |
| Any time | ECMO public hospital contract announcements (State tenders) |
| Any time | New pharma in-licensing deals to replace Bronchitol/Aridol earnings |
| Feb 2027 (expected) | HY27 results: revenue trajectory, H1 EBITDA (historically weaker), pump stabilisation, Jafron/SmartCanula traction, cash balance |
| By 30 Jun 2027 | Related-party royalty settlement election (GLK/Kingfisher/Tau): possible share issuance |
| Through FY2027 | Any capital raising; Prescribed List / PBS pricing changes |
Concluding analyst verdict
BTC Health has, over three years, rebuilt itself from a write-down-scarred pump distributor into a modest but genuinely diversified ANZ specialty medical-products group. The structural progress is real:
-
cardio has grown to 57% of revenue on the back of the Corcym valve business, PEARS and new cannulas
-
the cost base has been reset to about 41% of sales
-
gross margin is stable at 42.5%
-
the balance sheet is debt-free with 3.14c per share of net tangible assets
-
the second half of FY2026 produced the best EBITDA of the five-year series
However, the investment case remains one of execution under fragility. Headline revenue was flat in FY2026. ECMO conversion keeps slipping on State procurement timing. Pump conversion is slow. Most importantly, the September 2026 administration of Arna Pharma threatens BTC Pharma, the group's highest-earning unit, whose EBITDA exceeded the group's total reported EBITDA in FY2026. Statutory profits are essentially a function of directors' Level 3 valuations, and RSM's Key Audit Matters on valuation and going concern underline that dependence.
At about A$20m market capitalisation (about 1.8x NTA and about 1.8x EV/Sales on group revenue), the market is pricing in a successful cardio scale-up rather than current earnings. Upside depends on three things: ECMO tender wins, Corcym utilisation, and the new SmartCanula, Andocor and Jafron agencies more than offsetting the pharma shortfall while the cost base stays near A$4.2m. Downside comes from a prolonged Bronchitol/Aridol outage, further valuation write-downs, and dilutive funding of investee working capital.
Verdict: BTC Health is a speculative, illiquid micro-cap. The next 6–9 months — the Arna resolution and the HY27 result in February 2027 — are decisive. Until the company demonstrates sustained positive EBITDA without the pharma contribution, the balance of evidence favours a neutral-to-cautious stance, with NTA providing partial but valuation-dependent support.
Data integrity notes
Unaudited figures: All group revenue, gross profit, EBITDA and segment figures are management's unaudited non-statutory numbers.
Derived figures: FY2025 Infusion and Neurospinal segment revenue, FY2025 Corcym and PEARS revenue, half-year H2 figures, and FY2022–FY2023 parent cash are derived values and are flagged where used.
Not disclosed: Employees, geographic split within ANZ, ESG ratings, market share and market sizes are not publicly disclosed.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Role | Appointed | Tenure (at Oct 2026) | Age | Qualifications | Background | Shares held | Options held |
|---|---|---|---|---|---|---|---|---|
Dr Richard Treagus | Executive Chairman and Managing Director | 4 Aug 2014 | about 12.2 years | 60 | BScMed, MBChB, MPharmMed, MBA, MAICD | Physician and entrepreneur with 30+ years in international pharma and biotech; former Director of Neuren Pharmaceuticals Limited | 30,000,000 | 16,000,000 |
Martin Kahanovitz | Non-Executive Director; Chair of Audit & Risk Committee | 12 Jun 2025 (AR remuneration note gives 11 Jun 2025) | about 1.3 years | 58 | Chartered Accountant | CFO of Kahma Healthcare Group; Director of Biovac (The Biologicals and Vaccine Institute of Southern Africa) and Chair of its Finance & Risk Committee; nearly 30 years in biotech, pharma and medical industries | 3,850,000 | 0 |
Felicity McNeill | Non-Executive Director | 10 Oct 2022 | about 4.0 years | 54 | BA (Hons), MAICD | 25+ years in public and private sectors, including almost 15 years in regulatory and subsidy systems for medicines, vaccines, devices and diagnostics in Australia | 0 | 0 |
Executive Leadership Team
| Name | Title | Appointed | Prior role | Shares | Options |
|---|---|---|---|---|---|
Salesh Balak | CFO & Company Secretary | 17 Mar 2025 | Not disclosed in AR | 200,000 | 3,000,000 (1,000,000 vested) |
Joshua Kahanovitz | Chief Operating Officer | 17 Mar 2025 | Head of Finance (BTC) | 42,276,954 (substantial holder, 11.83%) | 2,000,000 (all vested) |
Oskar Hakansson | Director Commercial Operations / Business Development Director (per data providers) | — | — | — | — |
“—” = not publicly disclosed.
Directors' Remuneration
| Name | Salary and fees (AUD) | Annual leave (AUD) | Cash bonus (AUD) | Long service leave (AUD) | Superannuation (AUD) | Options (AUD) | Total (AUD) |
|---|---|---|---|---|---|---|---|
R Treagus | 340,000 | 0 | 0 | 0 | 0 | 20,000 | 360,000 |
M Kahanovitz | 35,714 | 0 | 0 | 0 | 4,286 | 0 | 40,000 |
F McNeill | 35,714 | 0 | 0 | 0 | 4,286 | 0 | 40,000 |
S Balak | 245,536 | 4,593 | 0 | 0 | 29,464 | 42,092 | 321,685 |
J Kahanovitz | 194,313 | 4,650 | 0 | 1,166 | 23,318 | 4,000 | 227,447 |
Total | 851277 | 9243 | 0 | 1166 | 61354 | 66092 | 989132 |
Directors' Remuneration (Annual)
| KMP total (AUD) | FY2025 | FY2026 |
|---|---|---|
Total KMP compensation | 874,648 | 989,132 |
Share-Based Incentives
| Grant date | Expiry | Exercise price (AUD) | Number |
|---|---|---|---|
23 Nov 2021 | 23 Nov 2026 | 0.120 | 6,000,000 |
10 Nov 2023 | 10 Nov 2028 | 0.049 | 12,000,000 |
2 Jun 2025 | 30 Jun 2030 | 0.080 | 3,000,000 |
Governance Overview
| Attribute | Status |
|---|---|
Board size | 3 |
Chair / CEO separation | No. Dr Treagus is Executive Chairman and Managing Director. This is contrary to ASX Corporate Governance Council Recommendation 2.5, which calls for an independent chair. |
Independent directors | At most 2 of 3 NEDs. Martin Kahanovitz shares a surname with COO and 11.8% holder Joshua Kahanovitz; no relationship is disclosed in the AR. Readers should check the Governance Statement before treating him as independent. |
Committees | Audit & Risk Committee (M Kahanovitz chair; F McNeill). No Remuneration or Nomination Committee. |
Meetings FY2026 | 9 Board meetings (100% attendance); 2 Audit & Risk meetings; 2 circular resolutions |
Related-party arrangements | (1) Chairman's fees via PharmaConnect. (2) Royalty agreements with GLK Medical, Kingfisher Medical and Tau Medical Supplies, all associated with COO Joshua Kahanovitz, for products introduced to BTC. Royalties are a percentage of gross profit, payable in BTC shares at 30-day VWAP less 10%. A$187,549 accrued at 30 June 2026 (FY2025 A$92,810); election deferred to 30 June 2027. |
Major Shareholders
| Holder | Shares | % |
|---|---|---|
NAOS Asset Management | 84,996,837 | 23.78 |
Joshua Kahanovitz (and associates) | 42,276,954 | 11.83 |
Richard Treagus (held via Mrs Karen Elizabeth Treagus) | 30,000,000 | 8.39 |
Visio Fund Management (Pty) Ltd | 24,590,164 | 6.88 |
Major Shareholders by Rank
| Rank | Holder | Shares | % |
|---|---|---|---|
| 1 | J P Morgan Nominees Australia Pty Limited | 97,739,153 | 27.34 |
| 2 | Mrs Karen Elizabeth Treagus | 30,000,000 | 8.39 |
| 3 | Sigma Company Limited (largest single line; three lines in top 20) | 16,856,467 | 4.72 |
| 4 | HSBC Custody Nominees (Australia) Limited | 16,796,164 | 4.70 |
| 5 | Namarong Investments Pty Ltd | 15,000,000 | 4.20 |
5= | Tau Investments Australia Pty Ltd | 14,092,318 | 3.94 |
5= | Kingfisher Medical Pty Ltd | 14,092,318 | 3.94 |
| 6 | GLK Medical Pty Ltd | 14,092,318 | 3.94 |
| 7 | Citicorp Nominees Pty Limited | 12,342,949 | 3.45 |
| 8 | Mr Thomas Christopher Fennell | 8,682,787 | 2.43 |
Major Shareholders by Ownership Metric
| Ownership metric | Value |
|---|---|
Top 20 holders | 82.86% |
Holders with more than 100,001 shares | 133 holders, 95.96% |
Holders with less than a marketable parcel | 414 |
Directors + KMP direct and associated holdings | About 76.4m shares (about 21.4%), incl. J Kahanovitz 42.3m, Treagus 30.0m, M Kahanovitz 3.85m, Balak 0.2m |
GLK / Kingfisher / Tau (Kahanovitz-associated per AR Note 17) | 42,276,954 shares combined — appears to be the same parcel as the J Kahanovitz substantial holding |
Competitive Landscape
Competitors by Segment
| Segment | Competitor | Type | Overlap with BTC | Relative positioning |
|---|---|---|---|---|
Cardio — heart valves | Edwards Lifesciences | Global OEM (direct in ANZ) | Surgical and transcatheter aortic valves vs Corcym/Perceval | Market leader in valves; vastly larger |
Cardio — heart valves | Medtronic | Global OEM | Surgical and transcatheter valves, cannulas, ECMO/CPB | Broad portfolio, direct sales force |
Cardio — heart valves | Abbott | Global OEM | Mechanical and tissue valves, structural heart | Large, direct |
Cardio — ECMO / ECLS | Getinge (Maquet Cardiohelp) | Global OEM | ECMO consoles and oxygenators vs Eurosets | Entrenched ECMO incumbent in Australian ICUs |
Cardio — ECMO / CPB / cannulas | LivaNova | Global OEM | Heart-lung machines, oxygenators, cannulas | Strong in perfusion |
Cardio — CPB / oxygenators | Terumo Cardiovascular | Global OEM | Oxygenators, CPB circuits | Strong in perfusion |
Cardio — hemoperfusion | CytoSorbents; Baxter (oXiris / CRRT) | Global OEMs | Blood purification vs Jafron | CytoSorb is the established sorbent brand |
Infusion pumps (pain) | Avanos Medical (ON-Q); Baxter; B. Braun; ICU Medical; Fresenius Kabi | Global OEMs | Elastomeric and electronic ambulatory pumps vs Elasto-Q/Micrel | Broad hospital contracts and bundling |
Neuro-spinal / biopsy | Stryker; Medtronic; Merit Medical; Becton Dickinson | Global OEMs | Biopsy needles, navigation markers, bone removal | Large-scale direct sales |
Respiratory pharma | Roche (Pulmozyme, dornase alfa); generic hypertonic saline suppliers; methacholine challenge alternatives | Pharma / generics | CF mucoactives vs Bronchitol; bronchial challenge vs Aridol | Competitive pressure explicitly cited for Bronchitol |
ANZ distribution peers | Device Technologies Australia (private); Paragon Care / CH2 (ASX-listed; merged with CH2 in 2024); Getz Healthcare; LMT Surgical; Emergo/others | Distributors | Compete for the same overseas OEM agency agreements and hospital accounts | Much larger scale, broader logistics |
Peer Comparison FY2026
| Metric | BTC Health (group) | Edwards Lifesciences | Getinge | LivaNova |
|---|---|---|---|---|
Latest revenue | A$10.27m (FY2026, unaudited) | About US$5.4bn (CY2024) | About SEK 35bn (CY2024) | About US$1.25bn (CY2024) |
Revenue growth | +0.4% (FY2026) | High single to low double digit (CY2024) | Low to mid single digit (CY2024) | High single digit (CY2024) |
Gross margin | 42.5% | About 75–80% | About 45–50% | About 65–70% |
EBITDA / operating margin | 1.3% EBITDA | About 25–30% operating | About 15–20% adj. EBITA | About 15–20% adj. operating |
R&D intensity | 0% | About 17% | About 5–7% | About 12–13% |
Recent Developments
Earlier 2024–early 2025 items are included for context.



